Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy

Peripheral T-cell non-Hodgkin lymphoma (PTCL) are heterogeneous, rare, and aggressive diseases mostly incurable with current cell cycle therapies. Aurora kinases (AKs) are key regulators of mitosis that drive PTCL proliferation. Alisertib (AK inhibitor) has a response rate ∼30% in relapsed and refra...

Descripción completa

Detalles Bibliográficos
Autores principales: Islam, Shariful, Vick, Eric, Huber, Bryan, Morales, Carla, Spier, Catherine, Cooke, Laurence, Weterings, Eric, Mahadevan, Daruka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725023/
https://www.ncbi.nlm.nih.gov/pubmed/29245981
http://dx.doi.org/10.18632/oncotarget.22222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725023/
https://www.ncbi.nlm.nih.gov/pubmed/29245981
http://dx.doi.org/10.18632/oncotarget.22222

Ejemplares similares